Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced ...

Prothena Corporation plc kept at Hold after mixed phase 2 results; key phase 3 readouts expected 2029. Click for this updated ...

Superagers’ memory capacity rivals that of younger adults. A new study suggests their brains’ robust production of new neurons may be why.

RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.

In hormone receptor (HR)–positive, HER2-negative advanced breast cancer, starting CDK4/6 inhibitors (CDK4/6i) in the first line of therapy did not improve overall survival (OS) compared with reserving ...

Ripples in the fabric of space-time called gravitational waves may be the key to solving the Hubble tension — one of the biggest nagging problems in physics.

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript March 5, 2026 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06428 EPS, expectations were $-0.06. Operator: Good day, ...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom ...

The study of the one-in-ten-billion kaon decay allows researchers to stress-test the Standard Model of particle physics.

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).